Disrupting vegf-vegfr1 interaction: De novo designed linear helical peptides to mimic the VEGF13-25 Fragment

The interaction between vascular endothelial growth factor (VEGF) and its receptors (VEGFR) has important implications in angiogenesis and cancer, which moved us to search for peptide derivatives able to block this protein-protein interaction. In a previous work we had described a collection of line...

Descripción completa

Detalles Bibliográficos
Autores: Balsera, Beatriz, Bonache de Marcos, María Ángeles, Reille-Seroussi, Marie, Gagey-Eilstein, Nathalie, Vidal, Michel, González-Muñiz, Rosario, Pérez de Vega, M. Jesús
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/162335
Acceso en línea:http://hdl.handle.net/10261/162335
Access Level:acceso abierto
Palabra clave:Peptides
Protein–protein interactions
VEGF-VEGFR1
Angiogenesis
α-helix
Descripción
Sumario:The interaction between vascular endothelial growth factor (VEGF) and its receptors (VEGFR) has important implications in angiogenesis and cancer, which moved us to search for peptide derivatives able to block this protein-protein interaction. In a previous work we had described a collection of linear 13-mer peptides specially designed to adopt helical conformations (Ac-SSEEXARNXAAXN-NH), as well as the evaluation of seven library components for the inhibition of the interaction of VEGF with its Receptor 1 (VEGFR1). This study led to the discovery of some new, quite potent inhibitors of this protein-protein system. The results we found prompted us to extend the study to other peptides of the library. We describe here the evaluation of a new selection of peptides from the initial library that allow us to identify new VEGF-VEGFR1 inhibitors. Among them, the peptide sequence containing F,W, and I residues at the 5, 9, and 12 positions, show a very significant nanomolar IC50 value, competing with VEGF for its receptor 1, VEGFR1 (Flt-1), which could represent a new tool within the therapeutic arsenal for cancer detection and therapy.